INTRODUCTION {#s1}
============

Cancers are series of diseases possessing high mortality in America, in which lung cancer, prostate cancer, breast cancer, colorectal cancer, ovarian cancer, and pancreatic cancer are mostly rangking forward \[[@R1]\]. Insulin-like growth factor-1 receptor (IGF-1R) induces the common pathways for normal cell growth, as well as cancer development, suggesting that IGF-1R is a potential target for cancer therapy \[[@R2], [@R3]\]. Various strategies have been used to target components of IGF-1R system, including small interfering RNA, antisense oligonucleotides, antisense RNA, triple helix-forming oligodeoxynucleotides, specific kinase inhibitors, single chain antibodies and fully humanized anti-IGF1R monoclonal antibodies \[[@R4]\]. Two of the most prevalent strategies are small-molecule tyrosine kinase inhibitors and monoclonal antibodies \[[@R5], [@R6]\]. Ganitumab (AMG-479), dalotuzumab (MK-0646), cixutumumab (IMC-A12), teprotumumab (R1507), and figitumumab (CP-751,871) are commonly used recombinant, fully human monoclonal antibodies against the insulin-like growth factor 1 receptor (IGF-1R). \[[@R7]\] These agents prevent binding of IGF-1 to IGF1R and subsequently inhibit down stream signaling, including PI3K/Akt pathway. \[[@R8], [@R9]\] PI3K-Akt Pathway can promote cell survival and growth in response to extracellular signals. It is highly regulated by multiple mechanisms, often involved in cross-talk with other signal pathways. \[[@R10]\] Therefore, inhibition of IGF-1R signaling and subsequent pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. \[[@R8], [@R11]\]

Up to date, outcomes of clinical studies about IGF-1R inhibitors seems to be unsatisfactory. We found only one study \[[@R12]\] seemed to have the active trend that IGF-1R inhibitors (AMG-479) improved the PFS or OS in advanced solid tumors. Some studies \[[@R13]--[@R15]\] revealed IGF-1R inhibitors could shorten OS and PFS. However, more studies \[[@R16]--[@R25]\] showed IGF-1R mono-antibodies had no significant value in cancer treatment. Three data from ongoing clinical trials (NCT00372996, 2015; NCT00887159, 2015; NCT00684983, 2016) also indicated insignificant cancer curative value of anti-IGF-1R agents. Herein, we conducted this meta-analysis by merging some similar study data. And overall and subgroup outcomes elucidated the situation of curative effects of these five anti-IGF-1R agents for patients with solid tumors. It should be noted that this analysis was designed to estimate the effect of the treatment with the combination of IGF-1R anti-agents and standard chemotherapy protocol. Thus statistically insignificant result was regarded as meaningful outcome as well. This meta-analysis was performed with up-to-date data.

RESULTS {#s2}
=======

Inclusion procedure {#s2_1}
-------------------

A total of 17 studies were enrolled to evaluate the curative effects of IGF-1R inhibitors for patients with solid tumors. These studies \[[@R12]--[@R14], [@R16]--[@R22]\] (NCT00372996, 2015; NCT00887159, 2015; NCT00684983, 2016) were selected according to the process shown in Figure [1](#F1){ref-type="fig"}. 3494 studies were identified in search, in which 707 were from Pubmed, 2512 from Embase, 179 from [Clinicaltrials.gov](http://Clinicaltrials.gov), and 96 from other sources. The elementary screening excluded 1050 duplicates and 2444 studies were left to the second screening. After the second screening, 35 studies were accessed for eligibility. Further selection excluded 18 studies that were undergoing without data published. Finally, 17 studies were enrolled into analysis.

![The Flow Chart of Study Selection](oncotarget-08-29501-g001){#F1}

Risk of bias assessment {#s2_2}
-----------------------

Our assessment result of risk of bias was shown in Table [1](#T1){ref-type="table"}. Most included studies were assessed as unclear risk of bias. One study \[[@R14]\] was assessed as low risk. Two studies \[[@R12], [@R24]\] were high risk.

###### Summary of bias of included studies

  Study ID   study                               Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting   Anything else, ideally prespecified   Overall bias
  ---------- ----------------------------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- ------------------------------------- --------------
  01         John F R Robertson et al., 2013     low                          low                      low                                      low                              low                       low                   low                                   low
  02         Francesco Sclafani et al., 2015     unclear                      unclear                  unclear                                  unclear                          low                       low                   unclear                               unclear
  03         H. L. Kindler et al., 2012          low                          high                     low                                      unclear                          low                       low                   unclear                               high
  04         C. S. Fuchs et al., 2015            unclear                      unclear                  unclear                                  unclear                          low                       low                   unclear                               unclear
  05         G. V. Scagliotti et al., 2014       low                          unclear                  unclear                                  unclear                          low                       unclear               unclear                               unclear
  06         Suresh S. Ramalingam et al., 2011   unclear                      unclear                  unclear                                  unclear                          low                       unclear               unclear                               unclear
  07         Philip A. Philip et al., 2015       low                          unclear                  low                                      unclear                          low                       unclear               unclear                               unclear
  08         Teresa Moran et al., 2014           unclear                      unclear                  unclear                                  unclear                          unclear                   unclear               unclear                               unclear
  09         Corey J. Langer et al., 2014        unclear                      unclear                  unclear                                  unclear                          unclear                   unclear               unclear                               unclear
  10         Nasser H. Hanna et al., 2015        unclear                      unclear                  high                                     high                             low                       unclear               unclear                               high
  11         Johann S. de Bono et al., 2014      unclear                      unclear                  unclear                                  unclear                          unclear                   unclear               unclear                               unclear
  12         A. L. Cohn et al., 2013             unclear                      unclear                  unclear                                  unclear                          unclear                   unclear               unclear                               unclear
  13         Eric Van Cutsem et al., 2015        low                          low                      low                                      low                              unclear                   unclear               unclear                               unclear
  14         Gottfried E. Konecny et al., 2014   unclear                      unclear                  unclear                                  unclear                          unclear                   unclear               unclear                               unclear
  15         NCT00372996, 2015                   unclear                      unclear                  unclear                                  unclear                          unclear                   unclear               unclear                               unclear
  16         NCT00887159, 2015                   unclear                      unclear                  unclear                                  unclear                          unclear                   unclear               unclear                               unclear
  17         NCT00684983, 2016                   unclear                      unclear                  unclear                                  unclear                          unclear                   unclear               unclear                               unclear

Low: Low risk of bias; Unclear: Unclear risk of bias; High: High risk of bias. The assessment was based on the Cochrane Collaboration\'s tool. John F R Robertson et al., 2013 was assessed the best quality. The rest studies were assessed as unclear with exception of two high-risk studies(Nasser H. Hanna et al., 2015; H. L. Kindler et al., 2012).

Main characteristics of included studies {#s2_3}
----------------------------------------

The basic characteristics of the 17 enrolled studies were listed in Table [2](#T2){ref-type="table"}. Of the enrolled studies, there were three of them with data exhibited in [Clinicaltrials.gov](http://Clinicaltrials.gov) but without formal article published (NCT00372996, 2015; NCT00887159, 2015; NCT00684983, 2016), while the other 14 with full articles. 3 studies contained two sets of data \[[@R15], [@R16], [@R23]\]. Three datas from two studies presented their confidental interval (CI) in proportion of 80% and 90%. We used stata to calculate their 95% CI as well as hazard ratio (HR). The published Year of enrolled studies ranged from 2012 to 2016. Sample size varied from 64 to 800. There were six types of cancer included: breast cancer, colorectal cancer, pancreatic cancer, lung cancer, prostate cancer, and ovarian cancer. More details about these cancers are: advanced hormone-receptor-positive breast cancer \[[@R14]\] (NCT00372996, 2015), metastatic colorectal cancer \[[@R15]\], wild-type KRAS metastatic colorectal cancer \[[@R21]\], mutant KRAS metastatic colorectal cancer \[[@R22]\], metastatic pancreatic cancer \[[@R12], [@R20]\], metastatic adenocarcinoma of the pancreas \[[@R23]\], and advanced-stage non-small-cell lung cancer \[[@R16], [@R17], [@R19], [@R24], [@R25]\] (NCT00887159, 2015). Study phase information: 2 phase-Ib/II studies, 1 phase-I/II study, 7 phase-II studies, 3 phase-III studies, 1 phase-II/III study, and 3 unknown phase studies. We analysed the potential cause of heterogeneity by sensitivity analysis and Begg test (Figure [2](#F2){ref-type="fig"}). Symmetric funnel plot and t value of 0.28 and −0.38 for OS and PFS respectively indicated a low publication bias in both of them. The statistical results showed as (A) adj. Kendall\'s Score (P-Q) = 3; Std. Dev. of Score = 18.27; Number of Studies = 14; z = 0.16; Pr \> \|z\| = 0.870; z = 0.11 (continuity corrected); Pr \> \|z\| = 0.913 (continuity corrected); (B) adj. Kendall\'s Score (P-Q) = −36; Std. Dev. of Score = 30.82; Number of Studies = 20; z = −1.17; Pr \> \|z\| = 0.243; z = 1.14 (continuity corrected); Pr \> \|z\| = 0.256 (continuity corrected) respectively. The sensitivity analysis did not revealed any over resulted study. Therefore, in all, the publication bias of our analysis was basically accepted. During article searching, we found there were ongoing trials without data published (NCT01327612; NCT02306161; NCT01122199; NCT01061788; NCT01708161; NCT00791154; NCT01042379; NCT00769483; NCT01868997; NCT01232452; NCT00955305; NCT01142388). We recommend that the results of these trials should be followed up in time, so that more precise conclusion could be updated.

###### Main characteristics of included studies

  Study ID   study                               Study phase   Pathologic Type     Patient number   NCT
  ---------- ----------------------------------- ------------- ------------------- ---------------- -------------
  01         John F R Robertson et al., 2013     II            Breast cancer       156              NCT00626106
  02         Francesco Sclafani et al., 2015     II/III        Colorectal cancer   351              NCT00614393
  03         H. L. Kindler et al., 2012          II            Pancreatic cancer   125              NCT00630552
  04         C. S. Fuchs et al., 2015            III           Pancreatic cancer   800              NCT01231347
  05         G. V. Scagliotti et al., 2014       III           Lung cancer         583              NCT00673049
  06         Suresh S. Ramalingam et al., 2011   II            Lung cancer         171              NCT00760929
  07         Philip A. Philip et al., 2015       Ib/II         Pancreatic cancer   200              NCT00617708
  08         Teresa Moran et al., 2014           I/II          Lung cancer         75               NCT00654420
  09         Corey J. Langer et al., 2014        III           Lung cancer         671              NCT00596830
  10         Nasser H. Hanna et al., 2015        II            Lung cancer         90               NCT00986674
  11         Johann S. de Bono et al., 2014      II            Prostate cancer     204              NCT00313781
  12         A. L. Cohn et al., 2013             II            Colorectal cancer   104              NCT00813605
  13         Eric Van Cutsem et al., 2015        Ib/II         Colorectal cancer   94               NCT00788957
  14         Gottfried E. Konecny et al., 2014   II            Ovarian cancer      170              NCT00718523
  15         NCT00372996, 2015                   LA\*          Breast cancer       219              NCT00372996
  16         NCT00887159, 2015                   LA\*          Lung cancer         152              NCT00887159
  17         NCT00684983, 2016                   LA\*          Breast cancer       64               NCT00684983

![Begg funnel plots and sensitivity analysis\
**A**. Begg funnel plot for overall OS; **B**. Begg funnel plot for overall PFS; **C**. Sensitivity analysis for OS; **D**. Sensitivity analysis for PFS.](oncotarget-08-29501-g002){#F2}

The situation of group allocation and patient demographics of studies were shown in Table [3](#T3){ref-type="table"}. The 3 studies that contained two sets of data \[[@R15], [@R16], [@R23]\] had three pallel arms. And although the study Kindler HL et al.,2012 \[[@R12]\] also comprised three groups, the one with protocol "Conatumumab 10 mg/kg +gemcitabine" was not suitable for the second inclusion criteria. Of all the studies, the median age ranged from 53.0 to 68.9 years. The percentage of male was ranged from 32.0% to 78.0%, with exception of the studies that specifically enrolled patients by sexual index \[[@R14], [@R17], [@R18]\] (NCT00372996, 2015; NCT00684983, 2016). Three studies \[[@R14]\] (NCT00372996, 2015; NCT00684983, 2016) were conducted to discuss breast cancer, and one study \[[@R18]\] was to discuss ovarian cancer. Therefore, these four studies only adopted female patients. Study that only adopted male patients was de Bono JS et al.,2014 \[[@R17]\], which aimed at prostate cancer. Patients recieved exemestane, irinotecan, cetuximab, gemcitabine, erlotinib, panitumumab, paclitaxel+carboplatin (PC), cisplatin+etoposide (CE), lapatinib+capecitabine (LC), and docetaxel+prednisone (PD) as combination therapeutic protocols.

###### Group allocation and patient demographics of studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study(ID)   Group                          Age,\          Sex        Race/ethnicity, n (%)                                                       
                                             mean & range                                                                                          
  ----------- ------------------------------ -------------- ---------- ----------------------- ------------------- --------------- --------------- ------------------
  01          (n=106)G                       61.0(54--70)   0(0)       106(100)                100(94)             2(2)            3(3)            1(1)

              (n=50)Plb                      62.0(55--66)   0(0)       50(100)                 47(94)              2(4)            0(0)            1(2)

  02          (n=119)iri+cet+Dal(weekly)     LA\*           86(72.3)   33 (27.7)               0(0)                0(0)            54(45.4)        62(52.1)+3(2.5)A

              (n=119)iri+cet+Dal(2-weekly)   LA\*           75(63.0)   44 (37.0)               0(0)                0(0)            59(49.6)        55(46.2)+5(4.2)A

              (n=116)iri+cet+Plb             LA\*           82(70.7)   34 (29.3)               0(0)                0(0)            49(42.2)        60(51.7)+7(6.1)A

  03          (n=42)G+gem                    66.0(37--82)   25(60)     17 (40)                 35(83)+CaucasianB   3(7)+AfricanC   0(0)            4(10)

              (n=41)Con+gem                  61.0(45--80)   24(59)     17 (41)                 32(78)+CaucasianB   3(7)+AfricanC   1(2)            5(12)

              (n=42)Plb+gem                  61.0(43--82)   26(62)     16 (38)                 37(88)+CaucasianB   3(7)+AfricanC   0(0)            2(5)

  04          (n=322)Plb+gem                 63.0(36--83)   188(58)    134 (42)                253(79)             3(1)            34(11)+30(9)D   1(\<1)

              (n=318)G(12)+gem               62.0(36--85)   159(50)    159 (50)                258(81)             4(1)            19(6)+35(11)D   2(1)

              (n=160)G(20)+gem               62.0(31--81)   85(53)     75 (47)                 129(81)             0(0)            14(9)+16(10)D   1(1)

  05          (n=293)F                       62.0(33--85)   228(78)    65(22)                  249(85)             7(2)            21(7)           16(5)

              (n=290)Control                 62.0(29--87)   225(78)    65(22)                  238(82)             7(2)            23(8)           22(8)

  06          (n=57)Er+Plb                   62.0           20(35)     37(65)                  55(96)              1(2)            0(0)            1(2)

              (n=57)Er+R1507(weekly)         63.0           18(32)     39(68)                  55(96)              1(2)            0(0)            1(2)

              (n=57)Er+R1507(3-weekly)       62.0           19(33)     38(67)                  56(98)              1(2)            0(0)            0(0)

  07          (n=100)Er+gem+cix              63.0           40(40)     60(60)                  LA\*                LA\*            LA\*            LA\*

              (n=100)Er+gem                  64.0           59(59)     41(41)                  LA\*                LA\*            LA\*            LA\*

  08          (n=38)Er                       59.0(36-80)    28(73.7)   10 (26.3)               0(0)                0(0)            2(5.3)          36(94.7)

              (n=37)Er+Dal                   62.0(45-77)    27(73)     10 (27)                 0(0)                0(0)            0(0)            37(100)

  09          (n=342)PC+F                    62.0(30-90)    261(76)    81(24)                  265(78)             9(3)            56(16)          12(4)

              (n=339)PC                      62.0(36-83)    260(77)    79(23)                  270(80)             4(1)            59(17)          6(2)

  10          (n=39)PC+cet                   60.0(42-89)    20(51)     19 (49)                 36(92)              3(8)            0(0)            0(0)

              (n=47)PC+cet+cix               60.0(44-76)    25(53)     22 (47)                 44(94)              2(4)            0(0)            0(0)

  11          (n=102)F+PD                    68.9           102(100)   0(0)                    94(92)              4(4)            0(0)            4(4)

              (n=102)PD                      67.9           102(100)   0(0)                    97(95)              2(2)            0(0)            3(3)

  12          (n=52)G+FOLFIRI                58.0(28--81)   24(46)     28 (54)                 41(79)              3(6)            7(13)           1(2)

              (n=52)Plb+FOLFIRI              59.0(32--80)   23(44)     29 (56)                 38(73)              4(8)            9(17)           1(2)

  13          (n=46)Pan+G                    62.0(33--81)   25(54)     21(46)                  LA\*                LA\*            LA\*            LA\*

              (n=48)Pan+Plb                  55.0(19--75)   28(58)     20(42)                  LA\*                LA\*            LA\*            LA\*

  14          (n=85)PC                       58.0(18-77)    0(0)       85(100)                 LA\*                LA\*            LA\*            LA\*

              (n=85)PC+G                     58.0(18-77)    0(0)       85(100)                 LA\*                LA\*            LA\*            LA\*

  15          (n=115)F+exe                   61.2           0(0)       115(100)                LA\*                LA\*            LA\*            LA\*

              (n=104)exe                     62.7           0(0)       104(100)                LA\*                LA\*            LA\*            LA\*

  16          (n=48)CE                       61.0(38-77)    25(52)     23(48)                  LA\*                LA\*            LA\*            LA\*

              (n=52)CE+vis                   64.0(52-87)    26(50)     26(50)                  LA\*                LA\*            LA\*            LA\*

              (n=52)CE+cix                   64.0(45-83)    25(48)     27(52)                  LA\*                LA\*            LA\*            LA\*

  17          (n=19)LC                       57.0(35-75)    0(0)       19(100)                 LA\*                LA\*            LA\*            LA\*

              (n=45)LC+cix                   53.0(29-78)    0(0)       45(100)                 LA\*                LA\*            LA\*            LA\*
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

Overall outcomes of OS and PFS {#s2_4}
------------------------------

We got data of OS (overall survival) from eleven studies \[[@R12], [@R14], [@R16], [@R19]--[@R24]\], and PFS (progression-free survival) data from 17 studies \[[@R12]--[@R14], [@R16]--[@R22]\] (NCT00372996, 2015; NCT00887159, 2015; NCT00684983, 2016). The analysis results were shown in Figure [3](#F3){ref-type="fig"} (OS: I^2^ = 37.1%, P = 0.080, HR = 1.08, 95% CI = 0.97-1.21; PFS: I^2^ = 0.0%, P = 0.637, HR = 1.05, 95% CI = 0.98-1.12), indicating that the relationship between prognosis and anti-IGF-1R agents was insignificant. But what\'s notable was that our analysis was not designed to draw definitive conclusions regarding efficacy, but rather to estimate the treatment effect on PFS and OS by IGF-1R anti-agents versus placebo.

![Forest plots of (A) hazard ratio (HR) for overall OS; (B) HRs for overall PFS](oncotarget-08-29501-g003){#F3}

In the OS analysis, the study Robertson JFR et al.,2013 \[[@R14]\] showed a significant result (HR = 1.78, 95% CI = 1.06-2.99) that the confidence interval (CI) range did not embrace 1. The result of lower confidence interval limit (lower CI limit)\>1, and harzard ratio (HR)\>1, indicated that the hazard risk rose by adding ganitumab (AMG-479). The rest studies lacked sufficient evidence to make conclusions, and that further analysis was required.

In the PFS analysis, only the study Cohn AL et al.,2013 \[[@R13]\] presented significant detrimental effect on cancer therapy (HR = 1.44, 95% CI = 1.06-1.96). The rest studies needed further analysis.

Based on the disappointing results, subgroup-analysis was conducted as follow.

Subgroup analysis {#s2_5}
-----------------

In order to make out how insignificant results were forged, subgroup analysis was conducted in two aspects, the mAbs and the cancer types.

### Subgroups allocated by anti-IGF-1R mAbs {#s2_5_1}

The study with significant result was shown in Figure [4](#F4){ref-type="fig"}, while studies with benefitial or detrimental trends but without statistical significance were shown in Figure [5](#F5){ref-type="fig"}, and studies with neither trending nor significant results were shown in Figure [6](#F6){ref-type="fig"}.

![Forest plots of HRs with statistical significance for OS or PFS in the subgroups of patients allocated by Anti-IGF1R agents\
OS-dalotuzumab (MK-0646).](oncotarget-08-29501-g004){#F4}

![Forest plots of HRs with tendency but without statistical significance for OS or PFS in the subgroups of patients allocated by Anti-IGF1R agents\
**A**. OS-Figitumumab (CP-751,871); **B**. OS-Teprotumumab (R1507); **C**. PFS-dalotuzumab (MK-0646); **D**. PFS-Figitumumab (CP-751,871).](oncotarget-08-29501-g005){#F5}

![Forest plots of HRs with insignificance for OS or PFS in the subgroups of patients allocated by Anti-IGF1R agents\
**A**. OS-Cixutumumab (IMC-A12); **B**. OS-Ganitumab (AMG-479); **C**. PFS-Cixutumumab (IMC-A12); **D**. PFS-Ganitumab; **E**. PFS-Teprotumumab (R1507).](oncotarget-08-29501-g006){#F6}

Three datas from two studies \[[@R15], [@R19]\] described the OS-dalotuzumab (MK-0646) in Figure [4](#F4){ref-type="fig"}, and the results (HR = 1.37, 95% CI = 1.09-1.74) indicated that dalotuzumab (MK-0646) should not be a suitable agents in cancer therapy.

Two study results \[[@R24], [@R25]\] (Figure [5A](#F5){ref-type="fig"}) described the OS-Figitumumab (CP-751,871) (HR = 1.14, 95% CI = 1.00-1.29), indicating that figitumumab (CP-751,871) may be harmful on cancer treatment. Two datas from one study \[[@R16]\] (Figure [5B](#F5){ref-type="fig"}) described the OS-Teprotumumab (R1507). The result (HR = 0.77, 95% CI = 0.55-1.02) hinted a trend that teprotumumab (R1507) may be beneficial to cancer therapy but not statistically significant. Certain conclusion needs further investigation to support. Three datas from two studies \[[@R15], [@R19]\] (Figure [5C](#F5){ref-type="fig"}) described the PFS-dalotuzumab (MK-0646), and four study datas \[[@R13], [@R24], [@R25]\] (NCT00372996, 2015) (Figure [5D](#F5){ref-type="fig"}) described the PFS-figitumumab (CP-751,871). The results showed worse trends but no statistical significance (HR = 1.18, 95% CI = 0.96-1.45; HR = 1.09, 95% CI = 0.94-1.26) for dalotuzumab (MK-0646) and figitumumab (CP-751,871) to treat cancer.

The OS-Cixutumumab (IMC-A12) was only insignificantly described by one study result (Teresa Moran et al., 2014) (Figure [6A](#F6){ref-type="fig"}) \[[@R20]\]. Six data from five studies \[[@R12], [@R14], [@R21]--[@R23]\] (Figure [6B](#F6){ref-type="fig"}) described the OS-ganitumab (AMG-479). The result (HR = 1.05, 95% CI = 0.85-1.28) was also insignificant. Four study datas \[[@R17], [@R20]\] (NCT00887159, 2015; NCT00684983, 2016) (Figure [6C](#F6){ref-type="fig"}) described the PFS-Cixutumumab (IMC-A12), seven datas from six studies \[[@R12], [@R14], [@R18], [@R21]--[@R23]\] (Figure [6D](#F6){ref-type="fig"}) described the PFS-ganitumab (AMG-479), and two datas from one study \[[@R16]\] (Figure [6E](#F6){ref-type="fig"}) described the PFS-teprotumumab (R1507). The results of these three subgroups (HR = 1.03, 95% CI = 0.83-1.28; HR = 0.99, 95% CI = 0.88-1.11; HR = 1.01, 95% CI = 0.77-1.32 respectively) were insignificant.

### Allocated by cancer types {#s2_5_2}

Two cancer types (prostate cancer and ovarian cancer) lacked data to describe the OS. In Figure [7](#F7){ref-type="fig"}-[8](#F8){ref-type="fig"}, the study with significant result was shown in Figure [7](#F7){ref-type="fig"}, while studies with detrimental trends but without statistical significance were shown in Figure [8](#F8){ref-type="fig"}, and studies with neither trending nor significant results were shown in Figure [9](#F9){ref-type="fig"}.

![Forest plots of HRs with statistical significance for OS or PFS in the subgroups of patients allocated by cancer types\
**A**. OS-breast cancer; **B**. OS-colorectal cancer; **C**. PFS-prostate cancer.](oncotarget-08-29501-g007){#F7}

![Forest plots of HRs with tendency but without statistical significance for OS or PFS in the subgroups of patients allocated by cancer types\
**A**. PFS-colorectal cancer; **B**. PFS-varian cancer.](oncotarget-08-29501-g008){#F8}

![Forest plots of HRs with insignificance for OS or PFS in the subgroups of patients allocated by cancer types\
**A**. OS-pancreatic cancer; **B**. OS-lung cancer; **C**. PFS-breast cancer; **D**. PFS-pancreatic cancer; **E**. PFS-lung cancer.](oncotarget-08-29501-g009){#F9}

There was only one study \[[@R14]\] (Figure [7A](#F7){ref-type="fig"}) result (HR = 1.79, 95% CI = 1.08-2.99) describing the OS-breast cancer, indicating significantly detrimental effect for breast cancer treated with IGF-1R inhibitors. Study for breast cancer patients treated by anti-IGF-1R agents was unexpected. Four datas from three studies \[[@R15], [@R21], [@R22]\] (Figure [7B](#F7){ref-type="fig"}) described the OS-colorectal cancer (HR = 1.29, 95% CI = 1.05-1.59), revealing significantly worse effects on colorectal cancer patients that treated with IGF-1R inhibitors. Only one study result \[[@R13]\] (Figure [7C](#F7){ref-type="fig"}) described the PFS-prostate cancer (HR = 1.44, 95% CI = 1.06-1.98). The result significantly indicated the harmful effect of IGF-1R inhibitors to treat prostate cancer.

Four datas from three studies \[[@R15], [@R21], [@R22]\] (Figure [8A](#F8){ref-type="fig"}) described the PFS-colorectal cancer (HR = 1.13, 95% CI = 0.94-1.37), and only one study \[[@R18]\] (Figure [8B](#F8){ref-type="fig"}) described the PFS-ovarian cancer (HR = 1.22, 95% CI = 0.81-1.83). Two results did not have significant effects of IGF-1R inhibitors in cancer therapies but indicating a detrimental trends in survival outcomes.

Four datas from three studies \[[@R12], [@R20], [@R23]\] (Figure [9A](#F9){ref-type="fig"}) described the OS-pancreatic cancer (HR = 0.97, 95% CI = 0.85-1.12), and five datas from four studies \[[@R16], [@R19], [@R24], [@R25]\] (Figure [9B](#F9){ref-type="fig"}) described the OS-lung cancer (HR = 1.04, 95% CI = 0.85-1.27). These two results revealed insignificant curative effects of IGF-1R inhibitors in pancreatic and lung cancer treatment.

In the PFS results, there were three study results \[[@R14]\] (NCT00372996, 2015; NCT00684983, 2016) (Figure [9C](#F9){ref-type="fig"}) describing the PFS-breast cancer (HR = 0.97, 95% CI = 0.82-1.15), four datas from three studies \[[@R12], [@R20], [@R23]\] (Figure [9D](#F9){ref-type="fig"}) describing the PFS-pancreatic cancer (HR = 0.95, 95% CI = 0.83-1.10), and seven datas from six studies \[[@R16], [@R17], [@R19], [@R24], [@R25]\] (NCT00887159, 2015) (Figure [9E](#F9){ref-type="fig"}) describing the PFS-lung cancer (HR = 1.06, 95% CI = 0.96-1.18). These three results all insignificantly described the curative effects, thus further study of IGF-1R inhibitors to treat cancer was needed.

DISCUSSION {#s3}
==========

Our analysis revealed the insignificant effects of IGF-1R inhibitors for solid tumor treatment so far. Harmful activity was even reported in some subgroups \[[@R13]--[@R15], [@R19], [@R21], [@R22]\], which was not accorded with the early study results \[[@R26], [@R27]\]. What\'s more, we noticed that in some trials the IGF-1R antibodies were well tolerated whereas in others they caused more severe side effects including hyperglycemia and neutropenia \[[@R14], [@R25]\].

It was meaningful to discuss the reasons of these phenomenon. As for the disappointing results, Sclafani F et al replied that it could be the potential of IGF-1R inhibition to accelerate tumour growth via aberrant feedback loops in intrinsically resistant tumours. This hypothesis would be supported in their study \[[@R15]\] by the higher dose intensity of dalotuzumab in arm A. Further more, they supposed it could be just a random effect. Robertson JFR et al considered that the limitations of study design may be of much concern, such as absence of an established biomarker and deficiency of hyperglycaemia as well as growth hormone concentrations measurement \[[@R14]\]. Another author Cohn AL et al thought that the disproportionately higher enrollment of patients with stage IV disease in the testing arm might have made the deviating outcomes. \[[@R13]\] Secondly, the adverse events could usually make the prognosis worse, but it was controversial. Robertson JFR et al found no safety issues that seemed to explain the negative efficacy findings \[[@R14]\], and the rate of serious adverse events reported in the study was similar to the rate reported in BOLERO-2 \[[@R28]\]. Moreover, a former work done by our laboratory also revealed the acceptability of adverse events caused by IGF-1R mAbs \[[@R29]\]. However, In the study conducted by de Bono JS et al \[[@R17]\], toxicity was substantially higher with testing group than with comparison group. And incidence of grade 3/4 treatment-related adverse events and severe adverse events (SAEs) increased, giving concern that the toxicity of combination treatment might detrimentally affect the results. There were other opinions to explain the pessimistic results. 1, Robertson JFR et al concluded in his study that ganitumab did not cross-react with insulin receptor and therefore did not inhibit IGF-2-mediated signaling via insulin receptor. IGF-1R inhibition alone was not sufficient if other pathways were activated (eg, EGFR) \[[@R14]\]. 2, Sclafani F et al analysed that poor recapitulation of tumor conditions as well as suboptimal patient selection might be the reasons \[[@R15]\]. 3, Wilson S et al thought It was possible that only in a minority of cases where IGF-1R was activated and exerted its oncogenic function \[[@R30]\], which turned targeting IGF-1R a subordinate method in some cases. 4, Garofalo C et al and Beltran PJ et al supposed a compensatory signaling existed via IGF2 through the insulin receptor \[[@R31], [@R32]\] which was not downregulated by ganitumab. 5, High frequency of downstream KRAS mutations in patients with pancreatic cancer was also considered as a potential explanation \[[@R21]\]. 6, Shin DH et al thought that targeting IR/IGF-1R was not enough to overcome growth and survival signals from downstream mutations in downstream pathways, such as PI3K/AKT axis. \[[@R33]\]

The diverse tolerabilities of IGF-1R mAbs in different trials refer to many possible mechanisms, most of which were unclear. We divided the enrolled studies into two groups by the median of any/severe adverse event rate. Then, we analyzed some potential factors to see the relationship between poor tolerabiliy group and good tolerability group \[[Supplement Table 1](#SD1){ref-type="supplementary-material"}; [Supplement Table 2](#SD1){ref-type="supplementary-material"}\]. The independent-sample t-test show that the adverse event rate are significantly different between poor tolerabiliy group and good tolerabiliy group in both [Supplement Table 1](#SD1){ref-type="supplementary-material"} and [Supplement Table 2](#SD1){ref-type="supplementary-material"}. Then likelihood ratio chi-square test and independent-sample t-test are correspondingly used to analyze cancer types, mono-antibodies, regimens, patient number, and median age. The results indicate that the factors mentioned above are not associated with the diverse tolerability. Although in [Supplement Table 2](#SD1){ref-type="supplementary-material"}, some potential factors (e.g. cancer types and regimens) show statistically significant association with tolerability, we still hold the conservative estimates. Because the sample size are too small. More studies are suggested to confirm this problem. In all, we suggest that some more frequently observed severe adverse events for specific cancer types should be paid adequate attention when using mono-anti-IGF-1R mAbs, and it was essential to choose the proper combination regimen to reduce AE-occurrences.

Suggestions on anti-IGF-1R mAb research and application {#s3_1}
-------------------------------------------------------

Most enrolled studies suggested researchers to select patients by specific biomarkers. In fact, there was an article providing evidence of the benefit to select patients by biomarkers \[[@R34]\]. Sclafani F et al found that high IGF-1 expression was predictive of poor outcome in the control arm but marked a subset of patients who appeared to benefit from the addition of weekly dalotuzumab to standard therapy. The study also showed that IGF-1 and IGF-2 might represent promising biomarkers predicting outcome with anti-IGF-1R- and anti-EGFR-targeted therapies \[[@R15]\]. Van Cutsem E et al investigated the correlation of efficacy endpoints with tumor MET, EGFR, PTEN, baseline circulating IGF1, IGF2, IGFBP1-3 and-6 protein levels. No strong evidence of predictive potential was found on efficacy endpoints for rilotumumab or ganitumab in combination with panitumumab \[[@R22]\]. The reasons might be the small number of patients per arm as well as potential imbalances in the arms for RAS mutations beyond KRAS exon 2. In study Cohn AL et al.,2013, PFS was associated with high circulating total IGF-1, IGF-2, and IGFBP-3, or associated with low IGFP-1 and IGFBP-2 in the ganitumab arm. In the placebo arm, low cytoplasmic PTEN expression was associated with longer PFS, indicating that the prognostic value of these markers requires further evaluation \[[@R13]\]. Based on the facts above, we recommend that anti-IGF-1R mAb studies should be conducted in biomarker-selected patients. Secondly, the combination regimen should consider the complementary efficacy of combination drugs on adverse effects. For example, hyperglycemia is the most common side effects of anti-IGF-1R mAbs \[[@R17], [@R35]\]. And metformin is an anti-diabetic drug with anti-cancer efficacy \[[@R36]\]. Thus, the combination of anti-IGF-1R mAbs and metformin may be a good choice.

Conclusions {#s3_2}
-----------

Our analysis used up-to-date data to show the pessimistic result of anti-IGF-1R mAbs on cancer therapy. However, it is too early to conclude IGF-IR antibodies have no utility as anti-cancer agents. It should be noted that up to November 2016, there were ongoing trials without data published (NCT01327612; NCT02306161; NCT01122199; NCT01061788; NCT01708161; NCT00791154; NCT01042379; NCT00769483; NCT01868997; NCT01232452; NCT00955305; NCT01142388). NCT01327612, NCT01122199, NCT01708161, NCT00769483, and NCT01868997 are in situation of "Active, not recruiting". NCT01061788 and NCT01042379 are in situation of "Recruiting". NCT00791154 and NCT01232452 are in situation of "completed" without any data published. While NCT02306161, NCT00955305, and NCT01142388 are in situation of "suspended", "terminated with results", and "Ongoing with results" respectively. NCT00955305 and NCT01142388 have posted the PFS and OS results in [www.clinicaltrials.gov](http://www.clinicaltrials.gov). However, the statistical analysis method of the two studies is Log Rank. And the PFS and OS results are also statistically insignificant. In NCT00955305, results for PFS and OS are p = 0.33 and p = 0.95 respectively, and in NCT01142388, the results are p = 0.58 and p = 0.50 respectively (all \>0.05). Nevertheless, we still recommend the rest trials should be followed up in time, so that more precise conclusion that whether anti-IGF-1R-mAbs behave good as anti-cancer agents or not could be updated.

Limitation {#s3_3}
----------

Firstly, The sources of enrolled studies were limited in Embase, Pubmed, [Clinicaltrials.gov](http://Clinicaltrials.gov) and other manual searching, which was not completely assured to cover all relevant data. Secondly, the data collected in our analysis were disappointing and the population were not large enough. Phase 3 clinical trials only occupied a small proportion in the enrolled studies. Moreover, Some enrolled studies possessed high risk of bias, which may, more or less, lead to deflection of the results.

MATERIALS AND METHODS {#s4}
=====================

Publication search {#s4_1}
------------------

We carried out a comprehensive systematic search of PubMed, EMBASE, and [Clinicaltirals.gov](http://Clinicaltirals.gov) (up to May 10, 2016). The following search key words were used to gain articles as comprehensive as possible: "ganitumab", "AMG479", "dalotuzumab", "MK 0646", "cixutumumab", "IMC-A12", "Teprotumumab", "R1507", "figitumumab", "CP751871", "IGF-1R", "Insulin-like growth factor-1 receptor", "tumor", "cancer", "combination therapy". Then subsequently, the searching strategy was used to identify the articles in relevance:"Search ( ( ( ( ( ( ( ( ( ( ( ( ( (Neoplasm \[Title/Abstract\]) OR Tumors \[Title/Abstract\]) OR Tumor \[Title/Abstract\]) OR Neoplasia \[Title/Abstract\]) OR Cancer \[Title/Abstract\]) OR Cancers \[Title/Abstract\]) OR Benign Neoplasms \[Title/Abstract\]) OR Neoplasms, Benign \[Title/Abstract\]) OR Benign Neoplasm \[Title/Abstract\]) OR Neoplasm, Benign \[Title/Abstract\]) OR Carcinoma \[Title/Abstract\]) OR Carcinomas \[Title/Abstract\])) AND ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (Combination Chemotherapy \[Title/Abstract\]) OR Drug Polytherapy \[Title/Abstract\]) OR Drug Polytherapies \[Title/Abstract\]) OR Polytherapies, Drug \[Title/Abstract\]) OR Polytherapy, Drug \[Title/Abstract\]) OR Therapy, Combination Drug \[Title/Abstract\]) OR Chemotherapy, Combination \[Title/Abstract\]) OR Chemotherapies, Combination \[Title/Abstract\]) OR Combination Chemotherapies \[Title/Abstract\]) OR Combination Drug Therapy \[Title/Abstract\]) OR Combination Drug Therapies \[Title/Abstract\]) OR Drug Therapies, Combination \[Title/Abstract\]) OR Therapies, Combination Drug \[Title/Abstract\]) OR Polychemotherapy \[Title/Abstract\]) OR Polychemotherapies \[Title/Abstract\]) OR Combined Antineoplastic Agents \[Title/Abstract\]) OR Antineoplastic Agents, Combined \[Title/Abstract\]) OR Agent, Combined Antineoplastic \[Title/Abstract\]) OR Agents, Combined Antineoplastic \[Title/Abstract\]) OR Antineoplastic Agent, Combined \[Title/Abstract\]) OR Combined Antineoplastic Agent \[Title/Abstract\]) OR Antineoplastic Combined Chemotherapy Regimens \[Title/Abstract\]) OR Drug Combinations, Antineoplastic \[Title/Abstract\]) OR Anticancer Drug Combinations \[Title/Abstract\]) OR Anticancer Drug Combination \[Title/Abstract\]) OR Drug Combination, Anticancer \[Title/Abstract\]) OR Drug Combinations, Anticancer \[Title/Abstract\]) OR Antineoplastic Drug Combinations \[Title/Abstract\]) OR Antineoplastic Drug Combination \[Title/Abstract\]) OR Combinations, Antineoplastic Drug \[Title/Abstract\]) OR Drug Combination, Antineoplastic \[Title/Abstract\]) OR Antineoplastic Chemotherapy Protocols \[Title/Abstract\]) OR Antineoplastic Chemotherapy Protocol \[Title/Abstract\]) OR Chemotherapy Protocol, Antineoplastic \[Title/Abstract\]) OR Protocol, Antineoplastic Chemotherapy \[Title/Abstract\]) OR Protocols, Antineoplastic Chemotherapy \[Title/Abstract\]) OR Cancer Chemotherapy Protocols \[Title/Abstract\]) OR Cancer Chemotherapy Protocol \[Title/Abstract\]) OR Chemotherapy Protocol, Cancer \[Title/Abstract\]) OR Chemotherapy Protocols, Cancer \[Title/Abstract\]) OR Protocol, Cancer Chemotherapy \[Title/Abstract\]) OR Protocols, Cancer Chemotherapy \[Title/Abstract\]) OR Chemotherapy Protocols, Antineoplastic \[Title/Abstract\])) AND ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (ganitumab \[Title/Abstract\]) OR AMG479 \[Title/Abstract\]) OR dalotuzumab \[Title/Abstract\]) OR MK 0646 \[Title/Abstract\]) OR MK0646 \[Title/Abstract\]) OR MK-0646 \[Title/Abstract\]) OR cixutumumab \[Title/Abstract\]) OR IMC-A12 \[Title/Abstract\]) OR Teprotumumab \[Title/Abstract\]) OR R 1507 \[Title/Abstract\]) OR R1507 \[Title/Abstract\]) OR R-1507 \[Title/Abstract\]) OR figitumumab \[Title/Abstract\]) OR CP751871 \[Title/Abstract\]) OR CP-751871 \[Title/Abstract\]) OR CP751,871 \[Title/Abstract\]) OR CP 751,871 \[Title/Abstract\]) OR CP-751,871 \[Title/Abstract\])) OR ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (IGF-1 Receptor) OR IGF 1 Receptor) OR Receptor, IGF-1) OR IGF-I Receptor) OR IGF I Receptor) OR Receptors, Insulin-Like-Growth Factor I) OR Receptor, IGF-I \[Title/Abstract\]) OR Receptor, IGF I \[Title/Abstract\]) OR Receptor, Insulin-Like Growth Factor I \[Title/Abstract\]) OR Receptor, Insulin-Like Growth Factor Type 1 \[Title/Abstract\]) OR Receptors, IGF-1 \[Title/Abstract\]) OR IGF-1 Receptors \[Title/Abstract\]) OR Receptors, IGF 1 \[Title/Abstract\]) OR IGF Type 1 Receptor \[Title/Abstract\]) OR Insulin-Like-Growth Factor I Receptor \[Title/Abstract\]) OR Insulin Like Growth Factor I Receptor \[Title/Abstract\]) OR Receptor, IGF Type 1 beta Subunit \[Title/Abstract\]) OR Receptor, IGF Type 1 alpha Subunit \[Title/Abstract\]) OR Insulin-Like Growth Factor Receptors \[Title/Abstract\]) OR Insulin Like Growth Factor Receptors \[Title/Abstract\]) OR Insulin-Like Growth Factor Receptor \[Title/Abstract\]) OR Receptors, Insulin-Like Growth Factors \[Title/Abstract\]) OR Receptors, Insulin Like Growth Factors \[Title/Abstract\]))". There are no restrictions on the types of studies and only publications published by English were included. The bibliographies of eligible studies were searched by hand for other relevant articles. The studies were selected following the steps in sequence: 1), Browse the tittles and eliminate irrelevant articles; 2), Skim the abstracts of the rest articles, and pick out those who satisfied the exclusion criteria and keep the ones accord with inclusion criteria; 3), Finally read the left articles and extract the data and information.

Inclusion criteria {#s4_2}
------------------

The inclusion criteria to obtain eligible studies: i), Studies that evaluated the efficacy of IGF-1R inhibitors by OS, PFS or both of them were eligible to be included. ii), Studies who contained two or more than two pallelel arms were included. Moreover, IGF-1R inhibitors must exert as controlled factors. iii), Studies that could be found with full articles or without full articles published but useful data was sufficient in [Clinicaltrials.gov](http://Clinicaltrials.gov) were included. iv), When the results were obtained from the same population and were published in several publications, only the most recent report or most informative one was included.

Exclusion criteria {#s4_3}
------------------

The exclusion criteria to exclude the ineligible studies: i), Studies without OS and PFS data. ii), The allocation method did not reveal the contral relationship but only escalation relationship among cohorts. iii), Studies of single group clinical assignment were excluded. iv), Those who were not cllinical studies were excluded.

Assessment of risk of bias {#s4_4}
--------------------------

The risk of bias assessment was important for the quality of analysis. Therefore, we assessed risk of bias by Cochrane Collaboration\'s tool from six key bias domains: selection bias, performance bias, detection bias, attrition bias, reporting bias and other bias. \[[@R37]\] The authors' judgements for a trial included low, unclear and high risk. They were defined as followed: Low risk of bias refers to the bias that is unlikely to alter the results seriously; Unclear risk of bias raises some doubt about the results; And the high risk of bias may alter the results seriously. Within a trial, judgement of low risk refered to low risk of bias for all key domains; Unclear risk of bias satisfied with low or unclear risk of bias for all key domains. And high risk of bias refered to high risk of bias for one or more key domains. The assessment result was shown in Table [1](#T1){ref-type="table"}. The study John F R Robertson et al., 2013 was assessed the best quality. The rest studies were assessed as unclear with exception of two high-risk studies (Nasser H. Hanna et al., 2015; H. L. Kindler et al., 2012).

All studies included in our analysis were assessed by two reviewers. When it came to discrepancies, the two reviewers decided to include or exclude studies after joint review.

Statistical analysis {#s4_5}
--------------------

The primary endpoint was PFS and the secondary endpoints was OS. The Progression-free survival (PFS) is a measure of treatment efficacy on a disease. It is the time that passes from a certain date (generally the first day of treatment, or the day in which a patient is enrolled in a clinical trial) to the date on which disease "progresses" or the date on which the patient dies, from any cause. The OS (also called overall survival) is the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer. In our analysis, measuring the PFS and OS is one way to see how well the IGF-1R inhibitors work for the patients suffering from solid tumors. In order to find an appropriate calculation model, We conducted heterogeneity analysis. Heterogeneity assumption was assessed by the I^2^ statistic and directed the analysis to be conducted in a random-effects model. Sensitivity analyses were conducted by removing one study each time. \[[@R38]\] Potential publication bias was evaluated by Begg\'s funnel plots and if the funnel plot showed asymmetry, it suggested a possible publication bias. And p≤0.05 used to assess the heterogeneity suggested statistically significantly bias in two-tailed level. All the statistical tests were performed with Stata 12.0 software.

SUPPLEMENTARY MATERIALS AND TABLES {#s5}
==================================
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